Trial Profile
To Evaluate efficacy and tolerability of IFN Beta-1a SC Treatment and Predictive Value of 6-Month MRI
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2020
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRISMS; PRISMS-2
- 26 May 2020 Results evaluating the duration of EDSS improvement after a therapy, presented at the 6th Congress of the European Academy of Neurology.
- 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology